In preclinical studies, MPCs induced cardiac arteriogenesis, reduced cardiac fibrosis, and prevented ventricular remodeling in ischemia-induced left ventricular dysfunction. 3, [5] [6] [7] Moreover, high-dose MPCs (225 million cells) improved cardiac function and neovascularization and reversed left ventricular remodeling in a sheep model of ischemic HF. 8 Allogeneic MPCs also provided cardioprotective benefits in sheep with doxorubicin-induced nonischemic cardiomyopathy. 3 Finally, MPCs have favorable immunoregulatory properties that allow for their allogeneic use. Human allogeneic MPCs express low levels of human leukocyte antigen ( HLA) class II surface antigens and lack costimulatory molecules (CD86 and CD80). 7 The strategy of using cells from a healthy young donor may improve efficacy in patients with HF in whom age and comorbidities contribute to the variability in the quality of autologous cells and reduce the overall benefits of cell therapy. 9 ,10 Accordingly, we conducted a phase 2, multicenter, doseescalation study to evaluate the feasibility and safety of 3 doses of immunoselected allogeneic MPCs (Mesoblast, Melbourne, Australia) in patients with chronic HF.
Methods

Trial Design and Patients
The primary end point of this study was to evaluate the feasibility, safety, and tolerability of 3 increasing doses (25, 75 , or 150 million cells) of immunoselected, culture-expanded allogeneic MPCs in patients with HF because of left ventricular systolic dysfunction of either ischemic or nonischemic pathogenesis. Safety was assessed by physical examination; clinical laboratory tests, including hematology, serum chemistry, and antibovine, antimurine, and anti-HLA antibody testing; and adverse events. Major adverse cardiac events (MACEs) were defined as cardiac death, myocardial infarction (MI), or the need for coronary revascularization and were assessed at 1 year. Adverse events that occurred during the mapping or injection procedures were considered as procedure related. Index cardiac catheterization periprocedural safety was assessed by transthoracic echocardiograms and telemetry monitoring. Holter monitoring was conducted on days 0, 1, 14, 30, 90, and 180.
The secondary end points assessed functional efficacy by using 2-dimensional (2D) echocardiograms with Doppler, multigated acquisition (MUGA), single photon emission computed tomography (SPECT) myocardial imaging, New York Heart Association classification, quality of life using the Minnesota Living with Heart Failure Questionnaire, and the 6-minute walk test (6MWT).
We also performed a post hoc analysis of HF-related MACE (HF-MACE), which was defined as cardiac death, successfully resuscitated cardiac death, or need for hospital admission for decompensated HF. This MACE definition, which is typical for congestive HF studies, is more appropriate for this patient population. Independent, blinded post hoc analyses were conducted for both MACE and HF-MACE for ≤36 months. The MACE analyses were adjudicated on the basis of the end point criteria generated by the Standardized Data Collection for Cardiovascular Trials Initiative. 11 Patients were allocated sequentially into 1 of 3 dosing cohorts with randomization to receive either transendocardial injections of allogeneic MPCs or mock mapping/injection procedures (control). The dosing cohorts were randomized sequentially in ascending order, beginning with the 25 million MPC group. There was a period of regulatory review between enrollment of each dosing cohort. Safety and MACE end points were evaluated for ≤3 years for all patients. Surrogate efficacy end points were evaluated at baseline, 3, 6 , and 12 months, except for SPECT and MUGA radionuclide angiography scan, which were performed at baseline and 6 months only ( Figure 1 ). The trial protocol was conducted according to the Declaration of Helsinki and was approved by the Institutional Review Board at all participating institutions and by the Data Safety and Monitoring Board. All patients provided written informed consent.
Patients with New York Heart Association class II or III HF who had a left ventricular ejection fraction (LVEF) <40% by baseline screening echocardiogram were recruited for the study and were 
Randomization and Masking
Patients were consented and randomly assigned within each cohort to either MPC or control treatment by using a randomization schedule generated via a standard procedure for creating random numbers (SAS) without stratification. All patients were blinded to treatment assignment as were all end point evaluators.
Procedures
Allogeneic, immunoselected, ex vivo expanded MPCs were derived from the mononuclear cell fraction of bone marrow obtained from the posterior iliac crest of a young healthy 26-year-old male donor. Cell procurement, processing, cryopreservation, and storage procedures were performed by a contract manufacturing facility (Lonza) under current good manufacturing practice conditions (Online Appendix I for details). Cryopreserved products were shipped to the clinical sites for local storage, and cells were thawed and injected according to study procedures. The off-the-shelf cryopreserved product was characterized by cell count; viability by trypan blue exclusion (Online Table I ); clonogenicity; surface antigen expression of STRO-1, STRO-3, CC-9, and HLA class I and II antigens; and karyotyping. 4, 12 The product was examined for the presence of donor infectious diseases, sterility, endotoxins, and mycoplasma (Online Table II) .
Patients randomized to the cell treatment groups received transendocardial injections of allogeneic MPCs administered via a NOGA Myostar catheter (Biosense Webster, Diamond Bar, CA) according to previously described injection and safety criteria. 13, 14 Each patient received 25, 75, or 150 million cells in a total of 15 to 20 injections of 0.2 mL each (not to exceed 4.0 mL total). Cell injections in patients with coronary artery disease were targeted to areas of the myocardium identified as ischemic on SPECT and as viable by electromechanical mapping (unipolar voltage >6.9 mV). Patients with nonischemic cardiomyopathy received the same number of transendocardial injections as did the ischemic patients; cells were injected into adjacent viable segments selected by the operator. Control patients underwent mock mapping and injection procedures with the investigators using a scripted dialog matching that used during cell injections in MPC-treated patients.
De novo humoral and cellular immune responses against the allogeneic donor cells were measured at baseline and at prespecified intervals, and potential clinical adverse consequences were evaluated. Anti-HLA antibodies were measured by flow cytometry using recipient sera and panels with microparticle beads expressing HLA antigens and were expressed as percent reactive antigens of the total antigens tested (percent reactive antigen). When the percent reactive antigen was >5% (considered a positive response), antibody specificity for donor antigens was determined using luminex-based bead assay (beads coated with recombinant HLA antigens) and was reported as mean fluorescence intensity (>1000 is positive). Donor specificity was identified when the antibody specificities were directed to the MPC donor HLA antigens. Adverse events that occurred within 30 days of detecting sensitization were reviewed for potential associations. Baseline screening indicating >20% reactivity against HLA antigens or any reactivity against MPC donor antigens excluded entry into the study. Recipient cellular immune responses against donor cells were measured in a mixed lymphocyte reaction, in which MPCs served as stimulators versus the patient's lymphocytes.
Exposure to bovine components occurs during the cell expansion process because of the use of fetal calf serum, and exposure to murine proteins may occur because of the use of murine-derived, antihuman stromal antibody in the immunoselection process. Thus, we screened patient sera for IgG and IgE immune responses to bovine and murine proteins. Screening assays were performed at baseline and at 30, 90, 180, and 360 days. All assays were done by using the ImmunoCAP 1000 platform (Phadia, Uppsala, Sweden). In this system, the allergen of interest was covalently coupled to a hydrophilic carrier polymer (cellulose) encased in a capsule. The allergen reacts with specific IgE or IgG antibodies in the sample, and the reaction was detected with anti-IgE or anti-IgG antibodies that were labeled with β-galactosidase. The fluorescent signal was measured; a higher signal indicated the presence of higher levels of specific antibody in the sample.
Procedural details for echocardiography, SPECT, MUGA, and Minnesota Living with Heart Failure Questionnaire are provided in the Online Appendix I.
Statistical Analysis
An adjudication of ischemic-MACE and HF-MACE was performed by a blinded independent cardiologist using standardized definitions after all surviving patients had completed 36 months of follow-up.
Descriptive data are presented by treatment, pooled MPC treatment, and control groups. Categorical variables are summarized by counts and percentages. Continuous variables are summarized by counts, mean, and SD. Where appropriate, differences between treatment and control groups were calculated, and significance was tested; a 2-sided P≤0.05 was considered significant. Demographics at baseline are summarized by treatment group for all randomized subjects and examined to assess the baseline comparability of the treatment groups. The continuous variables of subject age, weight, height, and body mass index are summarized using descriptive statistics. Treatment groups were compared for all continuous variables using a Wilcoxon rank sum test with treatment group as a factor. The categorical variables of patient sex, race, and ethnicity are summarized using descriptive statistics for each category. Treatment groups were compared for all categorical variables using a Fisher exact test.
Time-to-first-event data are reported by Kaplan-Meier plots and were analyzed for hazard ratios and risk reduction, and the log-rank test was used to test for significance between the treatments. Changes from baseline in left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), and LVEF at 3, 6, and 12 months are summarized and were analyzed using an F test from a repeated measures mixed model with treatment group, visit, and treatment-by-visit as factors, and the corresponding baseline value and treatment-by-baseline interaction as covariates. The pairwise comparisons were conducted at each time point by the contrast statement. Because of the nature of the exploratory study, there was no adjustment of the significance level with 0.05 for the multiple comparisons for these analyses. Analyses were conducted by using SAS v.9.2 (Cary, NC). The trial is registered at clinicaltrials.gov (NCT00721045).
Results
Patients
Between August 2008 and June 2010, a total of 60 patients were enrolled in the study into 3 cohorts (n=20 per group): 25, 75, and 150 million MPCs (Figure 1 ). Within each cohort, patients were randomly assigned to MPC treatment (n=15) or control (n=5) groups. The pooled MPC group had fewer women (2.2% versus 26.7%) and more patients with ischemic cardiomyopathy than did the control group (Table 1) .
Safety
The transendocardial injection of allogeneic MPCs in patients with HF was feasible, safe, and well tolerated. The incidence of adverse events was similar across all groups. Procedurerelated adverse events were seen in 3 MPC-treated patients (all in the 150 million cell group). In 1 patient, the procedure was stopped after 10 injections because of relative hypotension, which resolved. One patient had pericardial tamponade with a successful pericardiocentesis, and 1 patient had a retroperitoneal hematoma that resolved spontaneously. No patient had significant procedural-related arrhythmias. No sustained ventricular arrhythmias were seen in any group on the protocol-specified 24-hour Holter monitoring evaluations performed immediately post procedure. Subsequently, there were 2 episodes of sustained ventricular tachycardia in MPCtreated patients (one patient in the 25 million MPC group and one in the 75 million MPC group) that occurred >30 days after treatment. Routine interrogation of implantable cardioverterdefibrillators was not performed.
MACE was seen in 15 patients (Table 2) . Of the 45 MPCtreated patients, 10 (22%) had a total of 17 MACE, whereas 5 of 15 (33%) control patients had a total of 8 MACE. There were 2 cardiac deaths in the MPC groups (2/45 [4.4%], both in the 75 million MPC group) and 3 in the control group (3/15 [20%] ). Of the nonfatal MIs, 2 were ST-elevation MIs (both involving proximal stenosis of saphenous vein grafts) and 1 was a non-ST elevation MI (because of an embolus to the right coronary artery in a patient with underlying atrial fibrillation). Revascularization procedures occurred in 5 of 15 (33.3%) control patients and 12 of 45 (26.7%) MPC-treated patients. The majority of the revascularization MACE in MPC patients was associated with degeneration of previous longstanding saphenous vein grafts or intracoronary stents. We found no significant difference between MPC-treated and control patients for survival probability, MACE-free survival probability, MACE-free probability, and rates of all-cause mortality. Nine patients died during the study. Five MPC-treated patients died; one patient in the 25 million MPC group was involved in a car accident caused by another driver, two patients in the 75 million MPC group died of cardiac arrhythmias and a third of a hepatic tumor, and one 150 million MPC patient died of a retroperitoneal hemorrhage associated with anticoagulation therapy. Three control patients died of cardiac arrhythmias, and 1 died of postobstructive pneumonia.
Immunogenicity
All MPC-treated patients received cell product from the same donor. Mixed lymphocyte reaction studies indicated that the MPCs did not elicit proliferative responses from patients' cells. Immunogenicity results showed that 5 (11%) of the 45 MPC-treated patients developed donor-specific anti-HLA antibodies (Online Table III ); the MPC donor-specific responses were against HLA class I antigens but not HLA class II antigens. This response was transient in 3 patients (two 25 million MPC patients and one 150 million MPC patient) but persisted for ≤12 months in 2 patients in the 150 million MPC group. No clinical signs or symptoms were associated with an immunogenicity response.
Although increased levels of antibodies were seen in some MPC patients (Online Table IV ), no serious adverse events were attributed to sensitization to bovine, murine, or HLA proteins. No evidence of clinically meaningful changes in hematology and chemistry laboratory results was seen in MPCtreated or control patients.
Efficacy Results
All surviving patients completed a 36-month (±60 days) follow-up period.
Left Ventricular Volumes
Volume measurements were obtained by 2D echocardiography. Compared with the control group, the 150 million MPC group showed improvement in LVESV with a statistically significant decrease at 6 months (P=0.015) and a nonsignificant decrease at 12 months (Online Table V ). There were no statistically significant changes in LVESV in the other dose groups at any time point (Online Table V ). Figure 2 (top) shows the change from baseline in LVESV at 3, 6, and 12 months.
Similar to LVESV, there was a statistically significant decrease in LVEDV in the 150 million MPC group compared with control at 6 months (P=0.020) and a nonsignificant decrease at 12 months (Online Table V ; Figure 2 , bottom). There were no statistically significant changes in LVEDV in the other dose groups at any time point, except for an increase at 12 months in the 25 million MPC group (Online Table V) .
Left Ventricular Ejection Fraction
Left ventricular systolic performance was evaluated serially by using 2D echocardiography (baseline, 3, 6, and 12 months; Online Table V) and MUGA (baseline and 6 months; Online Table VI) . On echocardiography, LVEF increased significantly from baseline at 3 months in the 25 million MPC treatment group compared with control, but this difference was not maintained at follow-up. No significant differences from baseline were seen in the control or the 75 or 150 million MPC group at 3, 6, or 12 months.
MUGA results showed no significant differences in change from baseline at 6 months in control or any of the MPC-treated groups (Online Figure I) .
Functional Exercise Capacity
The 150 million MPC group consistently showed nonsignificant improvement in functional exercise over time compared with the control group (Online Table VII ). The control-corrected value for change from baseline at 12 months was 52.5 m (P=0.062) (Online Figure II) . There were no statistically significant differences between the 25 or 75 million MPC treatment group and the control group in change from baseline in distance travelled (Online Figure II) .
Other Efficacy Results
There were no consistent differences between the MPCtreated and control groups in myocardial perfusion by SPECT or in brain natriuretic peptide levels, New York Heart Association classification, or Minnesota Living with Heart Failure Questionnaire responses (Online Tables VIII-X).
Post Hoc HF-MACE Analysis
As a more appropriate definition of MACE in the patient population in this study, HF-MACE, defined as cardiac death, resuscitated ventricular fibrillation, and HF rehospitalization, was seen in 14 patients (Table 3) . No patient in the 150 million MPC group experienced HF-MACE. The composite HF-MACE end point was driven predominantly by hospital admission for decompensated HF (10 of 14 events); 8 of those 10 events occurred within the initial 12 months after trial enrollment. Overall, the incidence rate for time-to-first HF-MACE was 33% for the control group, 20% for the 25 million MPC group, 40% for the 75 million MPC group, and 0% for the 150 million MPC group. We found no difference for time-to-first HF-MACE between the control group and either the 25 or 75 million MPC group or between the 25 million and 75 million MPC groups, whereas the 150 million MPC group was significantly different for HF-MACE from all other groups compared individually (P=0.025 for the 150 million group versus control; Figure 3 ). The total number of HF-MACE allowing for multiple events per patient was 12 of 45 for the MPC patients (all in the 25 million and 75 million MPC groups) and 11 of 15 for the control group.
Discussion
In this study, we found that cell therapy with immunoselected, cultured MPCs derived from a healthy donor was safe and well tolerated in patients with chronic HF. Furthermore, our study suggests that the 150 million cell dose of MPCs may improve parameters of left ventricular remodeling and reduce HF-MACE.
Cell therapy trials in patients with HF have been primarily focused on the use of autologous bone marrow cells, which may have a degree of functional compromise associated with age or the presence of ischemic cardiomyopathy. 10, 15 Allogeneic cell therapy provides an alternative approach. In patients with ischemic cardiomyopathy, Hare et al 16 showed that allogeneic mesenchymal stem cells were safe and potentially efficacious. In this study, we used single donor-derived MPCs prepared by prospective immunoselection. This approach selectively enriches at a high purity level for STRO-3 + cells, yielding nonhematopoietic perivascular bone marrow stromal stem cells characterized by an extensive capacity for proliferation and differentiation.
3,4 Only 1 donor was used to create the cell product that was administered to all treated patients in this study. From a practical standpoint, cells from 1 donor cannot be used indefinitely; therefore, similarly selected allogeneic cells must eventually be derived from a new donor. Future studies are needed to assess this issue and examine the therapeutic equivalency among allogeneic products.
The host immune response and related clinical consequences are of potential concern in allogeneic cell therapy. In our study, donor-specific HLA sensitization was detected in 5 of 45 (11%) MPC-treated patients but was not temporally associated with adverse events. In transfusion and pregnancy, the rate of sensitization is usually 20% to 25%, and the response is not associated with clinical consequences. 17 One concern associated with the presence of donor-specific antigen is the possibility of loss of efficacy because of immune clearance of the product. Notably, we found the only sustained titers of donor-specific antigen in the 150 million MPC group, which had the best sustained efficacy response. Another concern is the development of tolerance to subsequent immunizing events, such as repeat MPC exposure or allograft transplantation, in MPC-sensitized patients. Mesenchymal lineage cells are being studied for use in inducing tolerance in the allograft setting, and the tolerance of repeat systemic administration of cells has been reported. 18 However, the immunologic responses to further alloantigen exposures in MPC-sensitized patients are not fully known and should be further studied. Donor selection strategies similar to those in current practice might be relevant for MPC-sensitized recipients.
In regard to procedural safety, of the 3 events that occurred in this study, 2 were transient, and 1 resolved with treatment. These events are not unexpected when performing left ventricular mapping and transendocardial cell injections in patients with HF. 15, 19 When this study was initiated, the mechanism underlying cell therapy in HF was thought to predominantly involve induction of neovascularization.
2,3,13,20,21 Accordingly, we used an ischemia-related, prespecified MACE composite variable. However, during the trial, the beneficial paracrine effects of cell therapy on adverse remodeling in HF became more apparent.
1,6,22-24 Thus, we conducted an independent, blinded post hoc analysis focused on HF-MACE, assessing relevant clinical HF end points.
In our prespecified analysis, MACE did not differ significantly between MPC-treated and control groups. Progression of the natural history of bypass graft (or stent) degeneration and native coronary artery disease occurred in both groups. Ischemic MACE was frequent in this population because the majority of patients had undergone coronary revascularization procedures before randomization, and many of the saphenous vein grafts were at least 10 years old. Therefore, it was not unexpected that transendocardial MPC injections did not decrease the prespecified MACE. In contrast with the prespecified MACE results, the HF-MACE analysis showed that treatment with high-dose (150 million cells) MPCs was superior to all other treatments, with no events occurring in that group up to 3 years after delivery. Overall, the efficacy parameters in this study did not show a dose response. However, our findings may suggest a threshold effect noted for highdose MPC treatment groups in terms of HF-MACE and left ventricular volumes.
The HF-MACE data are particularly relevant to the potential impact of MPCs on the natural history of HF because patients who are hospitalized for chronic HF have a significantly increased risk of repeat hospitalization and death. Approximately 50% of patients with a recent HF admission will be rehospitalized at least once within the following 6 months, and up to 35% will die within 1 year. 25 In our study, HF-MACE was predominantly driven by hospital admissions for decompensated HF, which accounted for 10 of 14 (71%) of the time-to-first HF-MACE and 17 of 23 (74%) of all HF-MACE, and was seen in all groups except patients treated with 150 million MPCs.
Recently, a meta-analysis of HF patients with reduced LVEF showed a significant positive correlation between longterm mortality and left ventricular remodeling as assessed by 2D echocardiography at 6 months. 26 Other clinical trials have shown changes in LVESV and LVEDV to be validated surrogate markers of left ventricular remodeling. 27, 28 In this study, changes from baseline data for LVESV and LVEDV were consistent with clinically relevant beneficial remodeling in the 150 million cell group. In contrast, there were no significant changes across any treatment groups for LVEF over time. The lack of significant time-related LVEF changes in the MPC-treated groups reflected parallel shifts in LVEDV and LVESV that were generally of similar magnitude and direction resulting in no clinically important net effect on left ventricular stroke volume and, therefore, LVEF. Our findings support those of a gene therapy study of sarcoplasmic reticulum Ca 2+ -ATPase in patients with advanced HF in which no appreciable change occurred in LVEF despite decreases in both LVESV and LVEDV 6 months after infusion in the high-dose group versus placebo. 29 Thus, results of innovative biological treatments such as cell therapy may be better evaluated by incorporating left ventricular volume data rather than by relying on the single variable of LVEF. Furthermore, it is important to consider that LVEF is highly dependent on ventricular loading conditions, heart rate, and contractile state. 30 Exercise intolerance is a defining symptom in patients with chronic HF, limiting physical activity and impairing quality of life. Compared with control patients, the 150 million MPC group showed improvement, albeit nonstatistically significant, in functional exercise capacity as assessed by the 6MWT at 6 and 12 months, and the control-corrected value for change from baseline at 12 months (52.5 m; P=0.062) exceeded the 50-m threshold often considered to be clinically relevant.
Study Limitations
The sample size for our study was small, especially for nonischemic cardiomyopathy patients. Ischemic disease predominated in all groups, and the low-dose group comprised only ischemic patients. The prespecified MACE was a limiting factor in analyzing this patient population because of the inclusion of patients with HF of ischemic or nonischemic origin. For this reason, we conducted the more pertinent post hoc analysis of HF-MACE. Also, there were baseline differences in subjective assessments of functional class, with more New York Heart Association class III patients in the control group than in the 150 million cell group. However, there were no differences in the objective measurements for LVEF, brain natriuretic peptide, or 6MWT distance at baseline. Other limitations included the use of mock rather than placebo injections, which could potentially weaken the results, and the lack of long-term (12 months) MUGA and SPECT data. In addition, infarct size data are not available because cardiac imaging was performed primarily by 2D noncontrast echocardiography. Moreover, our study was not powered to show statistical differences in efficacy end points, and positive statistical findings were not corrected for multiple comparisons. Nevertheless, we found statistically significant differences in HF-MACE and left ventricular remodeling variables. Finally, this was a single-blinded study; however, patient follow-up assessments were performed independently by a blinded reviewer, and laboratory and imaging data were analyzed by core laboratories blinded to patient treatment.
Conclusions
The use of allogeneic immune-selected MPCs offers a novel approach to cell therapy with an off-the-shelf, readily available cell product. We found that transendocardial injections of MPCs were safe without clinically symptomatic immune responses in patients with ischemic or nonischemic cardiomyopathy. Moreover, our study suggests that high-dose allogeneic MPC treatment may reduce HF-MACE and provide beneficial effects on adverse left ventricular remodeling.
What Is Known?
• Cell therapy with mesenchymal stem cells has been shown to be safe and potentially efficacious in patients with heart failure.
• Because of their immunoprivilege and immunosuppressive properties, mesenchymal stem cells have been used in an allogeneic setting for cell therapy in patients with ischemic cardiomyopathy.
• Allogeneic mesenchymal stem cells obtained by plastic adherence seem to be safe and potentially beneficial in treating patients with ischemic cardiomyopathy.
What New Information Does This Article Contribute?
• In this phase 2, multicenter, dose-escalation study, the transendocardial injection of allogeneic mesenchymal precursor cells (MPCs) isolated by immunoselection from the bone marrow of a healthy donor was found to be feasible and safe in patients with either ischemic or nonischemic heart failure (HF).
• The use of allogeneic MPCs in patients with HF did not result in any clinically symptomatic immune responses. High-dose allogeneic MPC therapy may decrease the clinical events associated with HF, such as rehospitalization and cardiac death, for ≤3 years, and could potentially reduce the effects of adverse ventricular remodeling, such as enlargement of the heart.
We conducted a phase 2, multicenter randomized clinical trial to examine the use of 3 doses of a novel population of immuneselected MPCs in patients with chronic HF of ischemic or nonischemic origin. The MPCs were obtained from a single healthy donor and selected from the bone marrow by using a specific antibody that isolates primitive stem/progenitor cells. Patients received either transendocardial injections of allogeneic MPCs or mock injections. This approach was found to be feasible and safe, and therapy with allogeneic cells did not elicit clinically meaningful immune responses. Treatment with high-dose MPCs reduced the volume measurements of the heart at 6 months, suggesting a decrease in heart size and a reversal in the remodeling of the heart that occurs in HF. Also, over a 3-year period, high-dose therapy reduced the occurrence of adverse events that are associated with HF, such as rehospitalization for worsening condition and cardiac death. Thus, the use of allogeneic, immune-selected MPCs offers a novel approach to cell therapy with an off-the-shelf readily available cell product.
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Trial design and patients
Patients were enrolled at 6 sites: Minneapolis Heart Institute, Mercy Gilbert Medical Center, Texas Heart Institute, University of California San Diego, University of Pittsburgh, and Swedish Medical Center.
Inclusion criteria
Patients had to meet all the following inclusion criteria to enter the study:
9. Female subjects of childbearing potential had to have a negative serum pregnancy test at screening. 10 . Willing and able to understand, sign, and date the ICF.
11. Willing to return for required follow-up visits.
12. Able to follow postoperative management program.
Exclusion criteria
Patients were excluded if any of the following applied:
1. Acute myocardial infarction in past 30 days.
2. Discharge of subject's ICD within 28 days of study procedure. NOGA catheter access to the left ventricle.
7. Cardiogenic shock, defined as the need for intravenous inotropic support, an intraaortic balloon pump, or mechanical circulatory support at the time of cell injections. 8 . Chronic atrial fibrillation (AF) or AF at the time of cell injections. 9 . Unprotected left main coronary artery disease > 50%. 10 . Ischemic or haemorrhagic stroke as diagnosed by computed tomography (CT)/magnetic resonance imaging (MRI) events within the last 3 months prior to enrolment. 25 . Treatment and/or an uncompleted follow-up treatment of any investigational therapy within 6 months before procedure and intent to participate in any other investigational drug or cell therapy study during the 3-year follow-up period of this study. 26 . Active participation in other research therapy for cardiovascular repair/regeneration. 27 . Prior recipient of stem precursor cell therapy for cardiac repair.
Cell production and characterization
The allogeneic MPCs used in this study are a STRO-3 immunoselected, culture-expanded, 
Doppler echocardiography
A baseline screening 2-D echocardiogram was obtained within 28 days before treatment.
Additional echocardiograms were performed on the day of treatment (no later than 2 hours after injection/mapping procedures) to assess for pericardial effusion, and at 3, 6, and 12-month follow-up. The imaging was performed by using parasternal long-and short-axis and apical longaxis, 2-, and 4-, and 5-chamber views. The echocardiogram images were stored digitally and provided to a qualified echocardiography laboratory to be read by a cardiologist who was blinded to the treatment group.
Images were assessed to determine diastolic wall thickness, left ventricular end-diastolic volume, left ventricular end-systolic volume, right ventricular volume, and LVEF (using the modified Simpson rule). A regional wall-motion score was generated by using a 17-segment model that assigned a value for wall motion to each segment. Specifically, a 3-point scoring system for wall motion was used with a value of 1 for normokinesia, 2 for hypokinesia, or 3 for akinesia/dyskinesia.
Single-photon emission computed tomography
Baseline SPECT imaging was performed at rest and after pharmacologic (adenosine) stress using standard clinical protocols. The procedure was repeated at 6 months in patients who had a known ischemic aetiology of heart failure. Images were displayed as raw data, multiplanar tomographic slices, and 3-dimensional sets for both rest and stress. Quantitative data analysis was performed by using standard clinical software. Each study was interpreted by an experienced nuclear medicine physician who was blinded to the patient's clinical situation and treatment group.
For patients with heart failure due to ischemic aetiology (as determined by the investigator based on cardiovascular history at screening), target segments for revascularization were selected before randomization based on the treating cardiologist's examination of SPECT perfusion results, the 17-segment analysis, and a 5-point scale for severity of defects. Segments that showed hypoperfusion as defined by a semi-quantitative severity score of 2, 3, or 4 were targeted for treatment. The baseline and 6-month SPECT scans were interpreted by a blinded reader who quantified the change in myocardial perfusion for the targeted segments.
Multi-Gated Acquisition (MUGA) scan-radionuclide angiography
Radionuclide angiography was performed at baseline and at 6 months according to a specified protocol agreed upon by the sponsor and the designated imaging laboratory. To maintain consistency across all sites, the equipment at each site was qualified to ensure that the data would be of sufficient quality for comparison. A qualified radiologist blinded to the patient's treatment group read the images.
Minnesota Living with Heart Failure Questionnaire
The MLHFQ outcomes were obtained at baseline and the 30-day and 3, 6, and 12-month followup. Surveys were mailed to patients with return postage for the 2 and 3-year study time points.
Overall subject satisfaction was determined by the physical component summary, mental component summary, and physical functioning subscale.
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